MRTX849
Mirati Therapeutics, Inc. · Advanced Colorectal Cancer; Advanced Non Small Cell Lung Cancer; Metastatic Colorectal Cancer; Metastatic Non Small Cell Lung Cancer
Key figures
Next catalyst
None scheduled
Only dates with a source are listed
Phase
Phase 3
Not recorded
Linked trials
2
From ClinicalTrials.gov
Latest FDA action
None on record
From Drugs@FDA
Recalls, shortages, patents and EU status at a glance
Key information
- Sponsor
- Mirati Therapeutics, Inc. Source: Company record for Mirati Therapeutics, Inc. (opens in a new tab)
- Indications
- Advanced Colorectal Cancer; Advanced Non Small Cell Lung Cancer; Metastatic Colorectal Cancer; Metastatic Non Small Cell Lung Cancer Source: Conditions from ClinicalTrials.gov (opens in a new tab)
- Designations
- None recorded
- Next catalyst
- None scheduled
Development timeline
- Preclinical Completed
- Phase 1 Completed
- Phase 2 Completed
- Phase 3 Current stageFirst trial start 23 Feb 20212 linked trials
- Filed Not yet
- Approved Not yet
Overview
- Mechanism
- Not recorded
- Route
- Not recorded
- Modality
- Not recorded
- Specialties
- Not recorded
Overview text is written by HealthTrade editors.
Key dates
No catalysts yet. Editors add each date together with its source.
FDA designations
No FDA designations are on record for MRTX849. Editors add each one with its source.
Filed application
No filed application is on record for MRTX849. Approvals are listed under FDA actions.
FDA advisory committees
No FDA advisory committee meetings are on record for MRTX849.
Clinical trials
| Trial | Title | Phase | Status | Enrollment | Primary completion | Results posted |
|---|---|---|---|---|---|---|
| NCT04793958ClinicalTrials.gov record for NCT04793958 (opens in a new tab) | Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10) | Phase 3 | Active, not recruiting | 461 (actual) | 16 Jan 2026 (actual) | No |
Publications listing NCT04793958 (1), newest first
Citations from PubMed, U.S. National Library of Medicine; abstracts are not stored. A publication lists this study’s NCT number and may be a review that cites many studies. | ||||||
| NCT04685135ClinicalTrials.gov record for NCT04685135 (opens in a new tab)KRYSTAL-12 | Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation | Phase 3 | Active, not recruiting | 453 (actual) | 30 Dec 2023 (actual) | Yes First posted Results on ClinicalTrials.gov for NCT04685135 (opens in a new tab) |
Posted results on ClinicalTrials.gov for KRYSTAL-12
Serious adverse events (All cause mortality and non serious adverse events were reported from first first dose of treatment (Day 1) till 28 days after last dose (Up to approximately 110 weeks). Serious adverse events were collected from date of signing of informed consent form till 28 days after last dose (Up to approximately 111 weeks).): Adagrasib 149 of 298; Docetaxel 50 of 140; Crossover Adagrasib 20 of 44 Source: ClinicalTrials.gov results for NCT04685135 (opens in a new tab)· imported Posted results as ClinicalTrials.gov prints them: primary outcome analyses and serious adverse event totals only. Registry facts, not reviewed by HealthTrade and not investment advice; filing-derived results are listed separately. Publications listing KRYSTAL-12 (2), newest first
Citations from PubMed, U.S. National Library of Medicine; abstracts are not stored. A publication lists this study’s NCT number and may be a review that cites many studies. | ||||||
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Posted results are shown as ClinicalTrials.gov prints them; results from company and journal sources are entered by editors and listed separately. Full result tables are on ClinicalTrials.gov.
Trial quality
About CT-VCALoading trial quality…
FDA actions
No FDA approvals on record for this drug.
FDA recalls load here.
FDA drug shortages load here.
Orange Book patents load here.
FAERS adverse event counts load here.
Papers and preprints load here.
Community discussion loads here.
EU status (EMA)
EMA's medicines data lists no human medicine with the same active substance as MRTX849.
Source: European Medicines Agency (EMA), medicines data download.
Related news
No recent headlines mention this drug.
Sources
- ClinicalTrials.gov NCT04793958 (opens in a new tab) Licence: public-domain. Official registry record this listing came from
- ClinicalTrials.gov NCT04685135 (opens in a new tab) Licence: public-domain. Official registry record this listing came from
Record updated .
Dates come from company and FDA disclosures and can change. Nothing on this page is investment advice.